1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EMA Says Spikevax Product Information To Be Updated To Include Paraesthesia As Rare Side Effect

01/20/2022 | 06:49am EDT

Jan 20 (Reuters) - European Medicines Agency:

* EMA: ASSESSMENT OF WHETHER VACCINATION CAN CAUSE CAPILLARY LEAK SYNDROME (IS ONGOING FOR PFIZER AND MODERNA COVID-19 VACCINES

* EMA SAYS FOR SPIKEVAX, PRODUCT INFORMATION WILL BE UPDATED TO INCLUDE PARAESTHESIA (UNUSUAL FEELING IN THE SKIN) AS A RARE SIDE EFFECT

* EMA: IN JANUARY 2022, PRAC CONCLUDED THAT TRANSVERSE MYELITIS SHOULD BE ADDED TO THE PRODUCT INFORMATION AS A SIDE EFFECT OF ASTRAZENECA VACCINE Further company coverage:


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.28% 10598 Delayed Quote.22.12%
MODERNA, INC. -4.04% 132.06 Delayed Quote.-48.00%
PFIZER, INC. 1.00% 53.41 Delayed Quote.-9.55%
All news about MODERNA, INC.
05/24Moderna's CEO Stephane Bancel to Exercise Shares, Intends to Donate Proceeds to Charity
MT
05/24GLOBAL MARKETS LIVE : Broadcom, Airbnb, Roche, Toyota, Uber
05/24WALL STREET STOCK EXCHANGE : Snap cut the rally short
05/24Rubius Therapeutics Names Noubar Afeyan Chairman; Shares Rise Pre-Bell
MT
05/24TRANSCRIPT : Moderna, Inc. Presents at UBS Global Healthcare Conference, May-24-2022 09:15..
CI
05/24MODERNA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/24Moderna testing potential monkeypox vaccines
RE
05/24Moderna CEO to Exercise 2013 Option, Donate Funds to Charity
DJ
05/24China's bet on homegrown mRNA vaccines holds back nation
AQ
05/23MODERNA : Statement Regarding Section 1498 Motion
PU
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 069 M - -
Net income 2022 11 501 M - -
Net cash 2022 18 081 M - -
P/E ratio 2022 4,85x
Yield 2022 -
Capitalization 52 528 M 52 528 M -
EV / Sales 2022 1,56x
EV / Sales 2023 3,16x
Nbr of Employees 2 700
Free-Float 90,6%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 132,06 $
Average target price 212,69 $
Spread / Average Target 61,1%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-48.00%54 740
LONZA GROUP AG-27.15%42 618
IQVIA HOLDINGS INC.-28.41%38 497
SEAGEN INC.-13.67%25 649
ICON PUBLIC LIMITED COMPANY-30.17%17 688
CELLTRION, INC.-26.77%16 131